Intravitreal bevacizumab in refractory neovascular glaucoma: A prospective, observational case series

Archives of Ophthalmology

Volumn 129, Issue 2, 2011, Pages 145-150

  Kotecha, Aachal ^a,b   Spratt, Alexander ^a   Ogunbowale, Lola ^a   Dell'Omo, Roberto ^a   Kulkarni, Avinash ^a   Bunce, Catey ^a   Franks, Wendy A ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EYE PAIN; EYE SURGERY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; IRIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RECURRENCE; TONOMETRY, OCULAR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 79951646776     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.350     Document Type: Article

References (53)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487. (Pubitemid 24356306)
2. Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol. 1997;124(4):521-529. (Pubitemid 27425876)
3. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105(2):232-237. (Pubitemid 28090825)
4. Duker JS, Brown GC. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology. 1989;96(1):92-95. (Pubitemid 19041334)
5. Sivak-Callcott JA, O'Day DM, Gass JD, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-1777, 1800.
6. Cashwell LF, Marks WP. Panretinal photocoagulation in the management of neovascular glaucoma. South Med J. 1988;81(11):1364-1368. (Pubitemid 19143918)
7. Wand M. Treatment of neovascular glaucoma. Ann Ophthalmol. 1979;11(10):1557-1559. (Pubitemid 10201371)
8. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28(5):696-702. (Pubitemid 351655121)
9. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859-870. (Pubitemid 44547437)
10. Kim YG, Hong S, Lee CS, et al. Level of vascular endothelial growth factor in aqueous humor and surgical results of Ahmed glaucoma valve implantation in patients with neovascular glaucoma. J Glaucoma. 2009;18(6):443-447.
11. Gartner S, Henkind P. Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol. 1978;22(5):291-312. (Pubitemid 8318531)
12. Günalp I, Gündüz K, Ozkan M. Causes of enucleation: a clinicopathological study. Eur J Ophthalmol. 1997;7(3):223-228. (Pubitemid 27439302)
13. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. 2009;(3):CD005392.
14. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26(5):495-511. (Pubitemid 44620390)
15. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye (Lond). 2008;22(1):82-86.
16. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142(6):1054-1056. (Pubitemid 44853889)
17. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571-1580.
18. Jonas JB, Golubkina L, Libondi T, Rensch F. Intravitreal bevacizumab for neovascular glaucoma. Acta Ophthalmol. 2010;88(2):e22-e23.
19. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucomawith intravitreal bevacizumab. Br J Ophthalmol. 2009;93(5):589-593.
20. Hansson SO. Uncertainty and the ethics of clinical trials. Theor Med Bioeth. 2006;27(2):149-167.
21. Spratt A, Ogunbowale L, Franks W. Bevacizumab: a compassionate way of doing business? Eye (Lond). 2007;21(6):890-891. (Pubitemid 46909230)
22. Abràmoff MD, Ramos LP, Jansen GH, Mourits MP. Patients with persistent pain after enucleation studied by MRI dynamic color mapping and histopathology. Invest Ophthalmol Vis Sci. 2001;42(10):2188-2192. (Pubitemid 32848845)
23. Weiss DI, Gold D. Neofibrovascularization of iris and anterior chamber angle: a clinical classification. Ann Ophthalmol. 1978;10(4):488-491.
24. Teich SA, Walsh JB. A grading system for iris neovascularization: prognostic implications for treatment. Ophthalmology. 1981;88(11):1102-1106. (Pubitemid 11031563)
25. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30(2):287-290. (Pubitemid 38366348)
26. dell'Omo R, Kulkarni A, Franks WA. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity. Acta Ophthalmol. 2008;86(6):698-700.
27. Maumenee AE. Retrobulbar alcohol injections; relief of ocular pain in eyes with and without vision. Am J Ophthalmol. 1949;32(11):1502-1508.
28. al-Faran MF, al-Omar OM. Retrobulbar alcohol injection in blind painful eyes. Ann Ophthalmol. 1990;22(12):460-462.
29. Kumar CM, Dowd TC, Hawthorne M. Retrobulbar alcohol injection for orbital pain relief under difficult circumstances: a case report. Ann Acad Med Singapore. 2006;35(4):260-265. (Pubitemid 43954360)
30. Custer PL, Reistad CE. Enucleation of blind, painful eyes. Ophthal Plast Reconstr Surg. 2000;16(5):326-329.
31. Mermoud A, Salmon JF, Alexander P, Straker C, Murray AD. Molteno tube implantation for neovascular glaucoma: long-term results and factors influencing the outcome. Ophthalmology. 1993;100(6):897-902. (Pubitemid 23163501)
32. Pastor SA, Singh K, Lee DA, et al. Cyclophotocoagulation: a report by the American Academy of Ophthalmology. Ophthalmology. 2001;108(11):2130-2138. (Pubitemid 33032791)
33. Bates DO, Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol. 1997;273(2 pt 2):H687-H694.
34. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653-660. (Pubitemid 36749213)
35. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331-371.
36. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007;16(5):437-439. (Pubitemid 47263045)
37. Mason JO III, Albert MA Jr, Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina. 2006;26(7):839-841. (Pubitemid 44386115)
38. Eid TM, Radwan A, el-ManawyW, el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol. 2009;44(4):451-456.
39. Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009;147:912-918.
40. Chen CH, Lai IC, Wu PC, et al. Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma. J Ocul Pharmacol Ther. 2010;26(1):111-118.
41. Elgin U, Berker N, Batman A, Simsek T, Cankaya B. Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma. 2006;15(5):466-470. (Pubitemid 44435003)
42. Saito Y, Higashide T, Takeda H, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol. 2010;88(1):96-102.
43. Alkawas AA, Shahien EA, Hussein AM. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C [published online ahead of print February 22, 2010]. J Glaucoma. 2010;19(9):622-626. doi:10.1097/IJG.0b013e3181ccb794.
44. Bartz-Schmidt KU, Thumann G, Psichias A, Krieglstein GK, Heimann K. Pars plana vitrectomy, endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 1999;237(12):969-975. (Pubitemid 30021286)
45. Kiuchi Y, Nakae K, Saito Y, Ito S, Ito N. Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1627-1632. (Pubitemid 44830822)
46. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48(4):1773-1781. (Pubitemid 351261365)
47. Beutel J, Peters S, Luke M, et al. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. 2010;88(1):103-109.
48. Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol. 2009;87(7):736-740.
49. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol. 2009;19(4):607-612.
50. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18(8):632-637.
51. Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93(4):457-462.
52. Gillies MC. What we don't know about Avastin might hurt us. Arch Ophthalmol. 2006;124(10):1478-1479. (Pubitemid 44537150)
53. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344-1349. (Pubitemid 44702055)